REG - Scancell Hlds - Block Listing Return and Total Voting Rights

Scancell HoldingsAnnouncement

01/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240701:nRSA4774Ua&default-theme=true

RNS Number : 4774U  Scancell Holdings Plc  01 July 2024

1 July 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Block Listing Return and Total Voting Rights

 

Change of Name of Nominated Adviser and Joint Broker

 

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, announces that it has allotted and issued a further
620,000 new ordinary shares of £0.001 each ("Ordinary Shares"), pursuant to
its block listing facility, in satisfaction of the exercise of share options
granted under the Company's existing options plan.

 

Following this issue, there will be a total of 929,599,977 Ordinary Shares in
issue. This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.

 

Block Listing Return

 

The Company makes the following notification pursuant to Schedule Six of the
AIM Rules for Companies regarding its existing block admission arrangements:

 

 Name of applicant:                                                                     Scancell Holdings plc
 Number and class of securities originally admitted:                                    2,880,000 ordinary shares of £0.001 each
 Date of admission:                                                                     17 April 2023
 Period of return:                                         From:                        17 October 2023  To:             30 June 2024
 Balance of unallotted securities under scheme(s) from previous return:                 620,000
 Plus: The amount by which the block scheme(s) has been increased since the             0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period (see          620,000
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:              0
 Total number of securities in issue at the end of the period                           929,599,977

Change of Name of Nominated Adviser and Joint Broker

The Company also announces that its Nominated Adviser and Joint Broker has
changed its name to Panmure Liberum Limited following completion of its own
corporate merger.

 

 For further information, please contact:
 Scancell Holdings plc                                                     +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)              +44 (0) 20 7886 2500

 Emma Earl, Freddy Crosslet, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                            +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby

 

 ICR Consilium                                  +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGFVNGVGDZM